Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

77.27 -0.44 (-0.56%)

Streaming Delayed Price Updated: 3:13 PM EDT, Apr 16, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	439,983
Open	77.21
Bid (Size)	77.25 (300)
Ask (Size)	77.29 (100)
Prev. Close	77.70
Today's Range	76.28 - 78.45
52wk Range	31.77 - 84.94
Shares Outstanding	160,500,999
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity

April 13, 2026

In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...

Via MarketMinute

BridgeBio Pharma Inc (NASDAQ:BBIO) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗

April 11, 2026

BridgeBio Pharma (BBIO) shows a strong technical uptrend with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders.

Via Chartmill

Performance

YTD	-1.2%	-1.2%
1 Month	+8.8%	+8.8%
3 Month	-0.8%	-0.8%
6 Month	+36.4%	+36.4%
1 Year	+125.7%	+125.7%

More News

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

March 30, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Inc (NASDAQ:BBIO) Posts Q4 Revenue Beat on Heart Drug Surge, Eyes Multiple 2026 NDA Submissions ↗

February 24, 2026

Via Chartmill

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

March 30, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

March 23, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 20, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

March 11, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

March 04, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio (BBIO) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

Via The Motley Fool

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

February 24, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Participate in March Investor Conferences

February 23, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Via Stocktwits

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 17, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Via The Motley Fool

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Via The Motley Fool

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

Via The Motley Fool

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

February 17, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

Via Finterra

BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? ↗

February 12, 2026

Via Stocktwits

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

February 12, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

Via MarketMinute

CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 27, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 27, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

January 16, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?

Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.

What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?

BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?

The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market

What is the current price of BridgeBio Pharma, Inc. - Common Stock?

The current price of BridgeBio Pharma, Inc. - Common Stock is 77.27

When was BridgeBio Pharma, Inc. - Common Stock last traded?

The last trade of BridgeBio Pharma, Inc. - Common Stock was at 04/16/26 03:13 PM ET

What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?

The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 12.40B

How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?

BridgeBio Pharma, Inc. - Common Stock has 12B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.